

# Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/RF7CE46F3C6EN.html>

Date: August 2018

Pages: 127

Price: US\$ 3,500.00 (Single User License)

ID: RF7CE46F3C6EN

## Abstracts

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H2 2018

## SUMMARY

According to the recently published report 'Receptor Tyrosine Protein Kinase ERBB 4 - Pipeline Review, H2 2018'; Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Receptor tyrosine-protein kinase erbB-4 is an enzyme that in humans is encoded by the ERBB4 gene. Receptor tyrosine-protein kinase erbB-4 is a receptor tyrosine kinase that is a member of the epidermal growth factor receptor subfamily. it plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis.

It is required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation, normal development of the embryonic central nervous system, especially for normal neural crest cell migration, normal axon guidance, mammary gland differentiation, induction of milk proteins and lactation. It acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors.

The report 'Receptor Tyrosine Protein Kinase ERBB 4 - Pipeline Review, H2 2018' outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 3, 1, 5, 1 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System and Gastrointestinal which include indications Gastric Cancer, Non-Small Cell Lung Cancer, Solid Tumor, Breast Cancer, Metastatic Breast Cancer, Colorectal Cancer, Esophageal Cancer, Glioblastoma Multiforme (GBM), Anaplastic Astrocytoma, Bile Duct Cancer (Cholangiocarcinoma), Cervical Cancer, Gallbladder Cancer, Head And Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Oligoastrocytoma, Carcinoma of Unknown Primary (Occult Primary Tumor/Cancer of Unknown Primary), Chordoma, Chronic Heart Failure, Crohn's Disease (Regional Enteritis), Diastolic Heart Failure, Endometrial Cancer, Ependymoma, Gastroesophageal (GE) Junction Carcinomas, Glioma, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Low-Grade Astrocytoma, Low-Grade

Glioma, Lung Adenocarcinoma, Medulloblastoma, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Brain Tumor, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Transitional (Urothelial) Tract Cancer, Necrotizing Enterocolitis, Neuroblastoma, Oligodendroglioma, Paranasal Sinus And Nasal Cavity Cancer, Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Pituitary Tumor, Primitive Neuroectodermal Tumor (PNET), Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Recurrent Malignant Glioma, Rhabdomyosarcoma, Sarcomas, Skin Cancer, Stroke, Systolic Heart Failure, Ulcerative Colitis, Urinary Tract Cancer and Uterine Cancer.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1)

The report reviews Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor

HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Overview

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development

Aslan Pharmaceuticals Pte Ltd

Avexegen Therapeutics Inc

Boehringer Ingelheim GmbH

Hanmi Pharmaceuticals Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Minerva Neurosciences Inc

Pfizer Inc

Puma Biotechnology Inc

XuanZhu Pharma Co Ltd

Zensun (Shanghai) Sci & Tech Co Ltd

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Drug Profiles

afatinib dimaleate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dacomitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FCN-411 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-5209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MIN-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

neratinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neucardin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NRG-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-113 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PB-357 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poziotinib - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
SKLB-1206 - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress

varlitinib - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress

XZP-5491 - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress

ynlitinib - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress

Z-650 - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Dormant Products

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Discontinued Products

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Jul 31, 2018: Puma Biotechnology Files New Drug Submission for NERLYNX in Canada

Jun 29, 2018: Puma Biotechnology Receives Positive CHMP Opinion Recommending Approval of NERLYNX for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

Jun 26, 2018: Puma Biotechnology Announces Results of CHMP Reexamination of

*Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Lik...*



MAA for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

Jun 04, 2018: Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations

Jun 02, 2018: Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting

Jun 01, 2018: Real-world analysis demonstrates Giotrif/Gilotrif (afatinib) dose adjustments reduced the frequency and intensity of adverse drug reactions without impacting efficacy

May 24, 2018: Researchers awarded multiple Department of Defense grants in next frontier of breast cancer genomics

May 17, 2018: ASLAN Pharmaceuticals to Present Two Posters on Varlitinib at ASCO

Apr 23, 2018: Spectrum Pharmaceuticals Announces Publication of Pozitotinib Data in Nature Medicine

Apr 17, 2018: ASLAN Pharmaceuticals Announces Presentation of New Pre-Clinical Data on Varlitinib in Hepatocellular Carcinoma at AACR

Apr 17, 2018: Spectrum Pharmaceuticals Highlights Data Showing Pozitotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in Chicago

Apr 10, 2018: Spectrum Pharmaceuticals Announces Update of MD Anderson's Phase 2 Data Studying Pozitotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer Patients

Apr 05, 2018: Specialised Therapeutics Asia Initiates Early Access Program For Neratinib

Apr 04, 2018: U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Dacomitinib to Treat Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations

Apr 02, 2018: NCCN Guidelines for Central Nervous System Cancers Include NERLYNX (neratinib) in Combination with Capecitabine or Paclitaxel as Treatment Options for Patients with Breast Cancer Brain Metastases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018  
Number of Products under Development by Therapy Areas, H2 2018  
Number of Products under Development by Indications, H2 2018  
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018  
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018  
Number of Products under Development by Indications, H2 2018 (Contd.3), H2 2018  
Number of Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018 (Contd.1), H2 2018  
Products under Development by Companies, H2 2018 (Contd.2), H2 2018  
Products under Development by Companies, H2 2018 (Contd.3), H2 2018  
Products under Development by Companies, H2 2018 (Contd.4), H2 2018  
Products under Development by Companies, H2 2018 (Contd.5), H2 2018  
Products under Development by Companies, H2 2018 (Contd.6), H2 2018  
Number of Products under Investigation by Universities/Institutes, H2 2018  
Products under Investigation by Universities/Institutes, H2 2018  
Number of Products by Stage and Mechanism of Actions, H2 2018  
Number of Products by Stage and Route of Administration, H2 2018  
Number of Products by Stage and Molecule Type, H2 2018  
Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2018  
Pipeline by Avexegen Therapeutics Inc, H2 2018  
Pipeline by Boehringer Ingelheim GmbH, H2 2018  
Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018  
Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2018  
Pipeline by Minerva Neurosciences Inc, H2 2018  
Pipeline by Pfizer Inc, H2 2018  
Pipeline by Puma Biotechnology Inc, H2 2018  
Pipeline by XuanZhu Pharma Co Ltd, H2 2018  
Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2018  
Dormant Products, H2 2018  
Dormant Products, H2 2018 (Contd.1), H2 2018  
Discontinued Products, H2 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018  
Number of Products under Development by Therapy Areas, H2 2018  
Number of Products under Development by Top 10 Indications, H2 2018  
Number of Products by Mechanism of Actions, H2 2018  
Number of Products by Stage and Mechanism of Actions, H2 2018  
Number of Products by Routes of Administration, H2 2018  
Number of Products by Stage and Routes of Administration, H2 2018  
Number of Products by Molecule Types, H2 2018  
Number of Products by Stage and Molecule Types, H2 2018

### COMPANIES MENTIONED

Aslan Pharmaceuticals Pte Ltd  
Avexegen Therapeutics Inc  
Boehringer Ingelheim GmbH  
Hanmi Pharmaceuticals Co Ltd  
Jiangsu Kanion Pharmaceutical Co Ltd  
Minerva Neurosciences Inc  
Pfizer Inc  
Puma Biotechnology Inc  
XuanZhu Pharma Co Ltd  
Zensun (Shanghai) Sci & Tech Co Ltd

## I would like to order

Product name: Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/RF7CE46F3C6EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RF7CE46F3C6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970